Stock Alert: Arbutus Biopharma Up 25% After Winning Patent Dispute With Moderna

(RTTNews) - Shares of Arbutus Biopharma Corp. (ABUS) gained over 25% on Friday morning after the U.S. Patent and Trademark Office ruled in favor of the company in a patent dispute with Moderna Inc. (MRNA)

ABUS is currently trading at $7.83, up $1.63 or 26.29%, on the Nasdaq.

The decision will help Arbutus make a royalty claim for products developed by Moderna using lipid nanoparticle delivery technology. This technology is currently being used by Moderna to develop a COVID-19 vaccine, known as MRNA-1273.

Moderna had filed the patent case against Arbutus Biopharma in January last year. Moderna argued that Arbutus patent for lipid nanoparticles, the technology used to deliver messenger RNA to a patients' cells, was unpatentable.

Meanwhile, Moderna shares are trading down 7%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More